{"name":"ZARS Pharma Inc.","slug":"zars-pharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Placebo Matrix/CHADD Patch","genericName":"Placebo Matrix/CHADD Patch","slug":"placebo-matrix-chadd-patch","indication":"Other","status":"phase_3"},{"name":"Placebo Peel","genericName":"Placebo Peel","slug":"placebo-peel","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ketoprofen matrix/placebo CHADD Patch","genericName":"Ketoprofen matrix/placebo CHADD Patch","slug":"ketoprofen-matrix-placebo-chadd-patch","indication":"Localized pain and inflammation (transdermal patch indication, likely musculoskeletal or arthritis-related pain)","status":"phase_3"}]}],"pipeline":[{"name":"Ketoprofen matrix/placebo CHADD Patch","genericName":"Ketoprofen matrix/placebo CHADD Patch","slug":"ketoprofen-matrix-placebo-chadd-patch","phase":"phase_3","mechanism":"Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.","indications":["Localized pain and inflammation (transdermal patch indication, likely musculoskeletal or arthritis-related pain)"],"catalyst":""},{"name":"Placebo Matrix/CHADD Patch","genericName":"Placebo Matrix/CHADD Patch","slug":"placebo-matrix-chadd-patch","phase":"phase_3","mechanism":"The Placebo Matrix/CHADD Patch does not contain an active pharmaceutical ingredient and is used as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo Peel","genericName":"Placebo Peel","slug":"placebo-peel","phase":"phase_3","mechanism":"Placebo Peel does not have a known mechanism of action.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9JSjIwVzUtQXFhVTJZNHVCQ0Y0TWRkZnpmS0cya0Z2UURsSzhpQ1h0LV9wZFNzeFV6Yi04X3JvN3VQVHJ4NHNsMHN3NzVuU2pwcy1oei1EYUlOSG85Zm53ejRfTXZiRzAx?oc=5","date":"2011-07-05","type":"pipeline","source":"Proactive Investors","summary":"Nuvo Research says EU marketing application for Pliaglis accepted - Proactive Investors","headline":"Nuvo Research says EU marketing application for Pliaglis accepted","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}